Apollomics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Apollomics, Lowers Price Target to $2
Maintaining Buy Rating on Apollomics Amid Clinical Setbacks and Pipeline Potential
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)
Apollomics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Apollomics, Maintains $17 Price Target
Promising Clinical Trial Results and Global Reach: A Strong Case for Apollomics' Buy Rating
Apollomics Analyst Ratings
Analysts Offer Insights on Financial Companies: Capital Bancorp (CBNK), Apollomics (APLM) and PNC Financial (PNC)
Buy Rating on Apollomics Based on Promising Future Prospects and High Potential of Vebreltinib in Cancer Treatment
Apollomics Analyst Ratings
Apollomics Analyst Ratings
Analysts Are Bullish on These Financial Stocks: Apollomics (APLM), CME Group (CME)
HC Wainwright & Co. Reiterates Buy on Apollomics, Maintains $18 Price Target
HC Wainwright & Co. Initiates Coverage On Apollomics With Buy Rating, Announces Price Target of $18
Apollomics (APLM) Has a New Rating From H.C. Wainwright
EF Hutton Remains a Buy on Apollomics (APLM)
EF Hutton Initiates Coverage On Apollomics With Buy Rating, Announces Price Target of $25
No Data